Abstract
Amiodarone has emerged as a potent agent for the management of patietits with reentrant supra ventricular tachycardias, atrial flutter, atrial fibrillation, and dysrhythmias associated with the preexcitation syndromes. Efficacy is reported betiveen 50 and 90% dependent upon the nature of the primary rhythm disturbance and population studied. Electrophysiological studies have not in general been helpful in predicting outcome with this agent. The drug may produce a wide array of toxic side effects, requiring cessation of therapy in less than 10% of patients. Our approach to the use of this agent relegates it to a second or third line of therapy in view of its complex pharmacokinetics and wide array of side effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
